PURPOSE: The CD47 molecule, often referred to as the "do not eat me" signal, is frequently overexpressed in tumor cells. This signaling pathway limits phagocytosis by macrophages. Our objective was to determine CD47 abundance in various soft tissue sarcomas (STS) to investigate whether it could serve as a potential evasion mechanism for tumor cells. Additionally, we aimed to assess the prognostic value of CD47 expression by examining its association with different clinicopathological factors. This study aimed to elucidate the significance of CD47 in the context of emerging anti-tumor targeting approaches. METHODS: In this retrospective study, formalin-fixed paraffine-embedded (FFPE) tumor tissues of 55 treatment-naïve patients were evaluated by immunohistochemistry for the abundance of CD47 molecule on tumor cells. The categorization of CD47 positivity was as follows: 0 (no staining of tumor cells), 1 + (less than 1/3 of tumor area positive), 2 + (between 1/3 and 2/3 of tumor area positive), and 3 + (more than 2/3 of tumor area positive for CD47). Next, we compared CD47 abundance between different tumor grades (G1-3). We used Kaplan-Meier survival curves with log-rank test to analyze the differences in survival between patients with different CD47 expression. Moreover, we performed Cox proportional hazards regression model to evaluate the clinical significance of CD47. RESULTS: CD47 is widely prevalent across distinct STS subtypes. More than 80% of high grade undifferentiated pleiomorphic sarcoma (UPS), 70% of myxofibrosarcoma (MFS) and more than 60% of liposarcoma (LPS) samples displayed a pattern of moderate-to-diffuse positivity. This phenomenon remains consistent regardless of the tumor grade. However, there was a tendency for higher CD47 expression levels in the G3 group compared to the combined G1 + G2 groups when all LPS, MFS, and UPS were analyzed together. No significant associations were observed between CD47 abundance, death, and metastatic status. Additionally, high CD47 expression was associated with a statistically significant increase in progression-free survival in the studied cohort of patients. CONCLUSION: This study highlights the potential of the CD47 molecule as a promising immunotherapeutic target in STS, particularly given its elevated expression levels in diverse sarcoma types. Our data showed a notable trend linking CD47 expression to tumor grade, while also suggesting an interesting correlation between enhanced abundance of CD47 expression and a reduced hazard risk of disease progression. Although these findings shed light on different roles of CD47 in STS, further research is crucial to assess its potential in clinical settings.
- MeSH
- antigeny CD47 metabolismus MeSH
- dospělí MeSH
- lidé MeSH
- lipopolysacharidy MeSH
- makrofágy patologie MeSH
- nádory měkkých tkání * patologie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- sarkom * terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Terapeutické možnosti u mCRC ve 3. a vyšší linii se neustále rozšiřují jak ve smyslu nových kombinací stávající léčby, tak o nové cílené malé molekuly. Výsledky dosavadních studií dokazují, že i vysoce předléčeným pacientům lze vhodnou terapeutickou intervencí prodloužit život při zachování jeho kvality. Současný rozvoj klinické onkologie nás nutí mít přehled nejen o aktuálně schválené léčbě, ale i o formujících se léčebných přístupech ve vyšších liniích léčby u pokročilého onemocnění.
Terapeutic possbilities in mCRC in 3rd and higher line of treatment are constantly expanding not only by new combinations of actual treatment possibilities, but also by discoveries of new small targeted molecules. Results of clinical studies prove that by right therapeutic intervention, we can prolong lives of highly pre-treated patients without worsening their quality of life. Ever evolving clinical oncology require us to have constant knowledge of actual therapeutic regimes and formation of new approach in higher lines of treatment in advanced illness.
- Klíčová slova
- regorafenib, tipiracil,
- MeSH
- bevacizumab aplikace a dávkování terapeutické užití MeSH
- cílená molekulární terapie metody MeSH
- erbB receptory antagonisté a inhibitory genetika MeSH
- fenylmočovinové sloučeniny aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- klinická studie jako téma MeSH
- kolorektální nádory * farmakoterapie genetika patologie MeSH
- kombinovaná farmakoterapie metody MeSH
- lidé MeSH
- protinádorové látky aplikace a dávkování terapeutické užití MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- pyridiny aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- pyrrolidiny aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- thymin aplikace a dávkování terapeutické užití MeSH
- trifluridin aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- záchranná terapie metody MeSH
- Check Tag
- lidé MeSH
